

Table 7
Ongoing clinical trials for COVID-19 treatments [240–425]

Treatment goal	Target	Drug	Company	Stage	Reference	Location
Prevention	Pre-exposure prophylaxis	Truvada	Gilead	Phase III	[240]	Spain
Prevention	Nitric oxide	GLS-1200	GeneOne Life Science	Phase II	[241]	USA
Prevention	Broad-spectrum antiseptic	Povidone-Iodine	University of Kentucky	Phase II	[242]	USA
Prevent respiratory infection	Pan antiviral immunotherapy	RTB101	Restorbio	Phase III	[243]	USA
Prevent respiratory illness	Anti-GM-CSF mAb	Otilimab	GSK	Phase II	[244]	USA, Spain
Prevent respiratory illness	Anti-GM-CSF mAb	Mavrilimumab	Kiniksa Pharmaceuticals	Phase II	[245]	USA
Prevent respiratory illness and heart failure	Anti IL-1B mAb	Ilaris	Novartis	Phase II	[246]	USA
Prevent shortness of breath	SSRI	Fluvoxamine	Washington University School of Medicine	Phase II	[247]	USA
Anti-viral growth	EF1A inhibitor	Aplidin	PharmaMar	Phase I	[248]	Spain
Anti-viral growth	IL-29 agonist	Peginterferon Lambda-1a	Eiger BioPharma	Phase II	[249]	USA
Anti-viral growth	Anti-factor XIIa mAb	CSL312	CSL Behring	Phase II	[250]	USA
Anti-viral growth	Plant-derived antiviral	AQCH	Sun Pharma	Phase II	[251]	India
Anti-viral growth	HIV protease inhibitor	Kaletra (Lopinavir – Ritonavir)	Abbvie	Failed trial	[252–255]	Multiple locations
Anti-viral growth	Broad-spectrum antiviral	Arbidol	Pharmstandard	Failed clinical trial	[256]	China, Iran
Anti-viral growth	Broad-spectrum antiviral	EIDD-2801	Ridgeback Bio	Phase I	[257]	United Kingdom
Anti-viral growth	Broad-spectrum antiviral, antiparasitic	Alinia	Romark Laboratories	Phase III	[258–261]	Multiple locations
Anti-viral growth	Broad-spectrum antiparasitic	Ivermectin	Tanta University	Phase II/III	[258]	Multiple locations
Anti-viral growth	Cleaves sialic acid	Fludase (DAS181)	Ansun Biopharma	Phase III	[262, 263]	Multiple locations
Anti-viral growth	Adenosine analog	Remdesivir	Gilead	Approved/ EUA/ Phase III	[264, 265]	Multiple locations
Anti-viral growth	Adenosine analog	Galidesivir	BioCryst Pharmaceuticals	Phase I	[266]	Brazil
Anti-viral growth	Guanosine analog	Virazole	Bausch Health	Phase II	[267]	Canada
Anti-viral growth	Pyrimidine analog	Clevudine	Bukwang Pharmaceutical	Phase II	[268]	Korea
Anti-viral growth	RNA polymerase inhibitor	Avigan (Favipiravir)	Fujifilm	Phase III	[269–272]	Multiple locations
Anti-viral growth	Non-nucleoside reverse transcriptase inhibitor	Elpida (elsulfavirine)	Viriom	Phase II	[273]	Russian Federation
Anti-viral growth	Nucleoside reverse transcriptase inhibitor	Azvodine	Capital Medical University	Phase II	[274]	China
Anti-viral growth	ACE-2 inhibitor	Chloroquine/ Hydroxy-chloroquine	Multiple locations	Failed / Ongoing	[275, 276]	Multiple locations
Anti-viral growth	VEGF inhibitor	Avastin	Roche	Phase II/III	[277, 278]	China, Italy
Anti-viral growth	Inhaled corticosteroid	Alvesco (ciclesonide)	Covis Pharma	Phase III	[279]	Korea, Japan
Anti-viral growth	H2 antagonist	Pepcid (Famotidine)	Northwell Health	Phase II	[280]	USA
Anti-viral growth	Anti-Spike (S), SARS-CoV – 2 mAb	REGN-COV2 (REGN10933 + REGN10987)	Regeneron	Phase III	[281, 282]	USA